Showing results (51-60 of 422) with videos related to
Sort By:
Pageof 43
Nature|May 6, 2026
Two decades of PARP inhibitor synthetic lethality in cancerChristopher J Lord, Andrew N J Tutt, Alan AshworthPlos One|November 13, 2012
NLK is a novel therapeutic target for PTEN deficient tumour cellsAna M Mendes-Pereira, Christopher J Lord, Alan AshworthNature Reviews. Drug Discovery|June 30, 2007
Utilizing RNA interference to enhance cancer drug discoveryElizabeth Iorns, Christopher J Lord, Nicholas Turner, et al.Nature Clinical Practice. Oncology|August 31, 2007
Mechanisms of disease: angiogenesis and the management of breast cancerSusana Banerjee, Mitch Dowsett, Alan Ashworth, et al.Annual Review of Medicine|October 24, 2014
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitorsChristopher J Lord, Andrew N J Tutt, Alan AshworthNature Cell Biology|April 2, 2008
BRCA1 and stem cells: tumour typecastingMatthew J Smalley, Jorge S Reis-Filho, Alan AshworthNature Reviews. Drug Discovery|November 13, 2019
Synthetic lethality as an engine for cancer drug target discoveryAlan Huang, Levi A Garraway, Alan Ashworth, et al.Cancer Research Communications|November 26, 2025
Identification of a Two-Gene Biomarker Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer CellsXuxu Gou, Huadong Chen, Morgan E Diolaiti, et al.Cell|April 5, 2011
Genetic interactions in cancer progression and treatmentAlan Ashworth, Christopher J Lord, Jorge S Reis-FilhoNature Reviews. Clinical Oncology|September 1, 2011
Challenges translating breast cancer gene signatures into the clinicBritta Weigelt, Lajos Pusztai, Alan Ashworth, et al.Pageof 43